Trials / Recruiting
RecruitingNCT06001086
A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer
A Multicenter, Open Phase II Clinical Study to Evaluate the Efficacy and Safety of Disitamb Vedotin Combined With Pyrotinib in Previously Untreated Histologically Proven HER2 Positive Early Breast Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the efficacy and safety of Disitamb Vedotin combined with pyrotinib in HER2 positive early breast cancer
Detailed description
The main goal of this clinical trial is to evaluate the efficacy of Disitamb Vedotin combined with pyrotinib in previously untreated histologically proven HER2 positive early breast cancer and evaluate the PCR DFS,OS and safety of the subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Disitamb Vedotin ,pyrotinib | Disitamb Vedotin combined with pyrotinib |
Timeline
- Start date
- 2023-11-01
- Primary completion
- 2026-08-01
- Completion
- 2026-12-31
- First posted
- 2023-08-21
- Last updated
- 2023-12-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06001086. Inclusion in this directory is not an endorsement.